Emmessar Biotech

Why is Emmessar Biotech & Nutrition Ltd falling/rising?

As of 19-Jun, Emmessar Biotech & Nutrition Ltd's stock price is rising to 25.70, reflecting a 3.84% increase. This short-term gain is notable despite a year-to-date decline of 12.44%, and it may be driven by temporary momentum rather than long-term stability, as indicated by decreased investor participation.

As of 19-Jun, Emmessar Biotech & Nutrition Ltd's stock price is rising, currently at 25.70, reflecting an increase of 0.95 or 3.84%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.84% today, indicating strong relative performance. Additionally, it has been gaining for the last two days, accumulating a total return of 4.43% during this period. <BR><BR>Despite the positive short-term performance, it is important to note that the stock has experienced a decline over longer periods, with a year-to-date drop of 12.44% and a one-year decline of 23.83%. However, the current rise is supported by the stock trading above its 5-day and 20-day moving averages, which suggests a short-term bullish trend. <BR><BR>On the downside, there has been a significant decrease in investor participation, with delivery volume falling by 72.34% against the 5-day average, which may indicate a lack of sustained interest. Nonetheless, the stock remains liquid enough for trading, based on its average traded value. Overall, the recent gains appear to be driven by short-term momentum rather than long-term stability.

Which are the latest news on Emmessar Biotech?

What does Emmessar Biotech do?

Emmessar Biotech & Nutrition Ltd manufactures Super Specialty Fine Chemicals and operates in the Commodity Chemicals industry. As of March 2026, it reported net sales and profit of 0 Cr, with a market cap of INR 13 Cr.

Overview: <BR>Emmessar Biotech & Nutrition Ltd is engaged in the manufacturing of Super Specialty Fine Chemicals and operates within the Commodity Chemicals industry, categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally established on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL). It has developed numerous Specialty Fine Chemicals and received official recognition for its R&D from the DSIR, Ministry of Science & Technology, Government of India, in early 1996. The latest quarterly results reported net sales and net profit of 0 Cr for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 13 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.90 <BR>Return on Equity: 5.30% <BR>Price-to-Book: 1.63 <BR><BR>Contact Details: <BR>Address: Plot No T-3/2 MIDC Area, P O Box No 39 Taloja Raigad Maharashtra : 410208 <BR>Tel: 91-022-20870587 <BR>Email: investors@ebnl.co.in/emmessar@vsnl. <BR>Website: http://www.ebnl.co.in

How big is Emmessar Biotech?

As of 10th June, Emmessar Biotech & Nutrition Ltd has a market capitalization of 13.00 Cr, with recent net sales of 0.36 Cr and net profit of 0.43 Cr over the last four quarters. Shareholder's funds are 7.71 Cr, and total assets are 9.22 Cr as of March 2025.

As of 10th June, <BR><BR>Market Cap: Emmessar Biotech & Nutrition Ltd has a market capitalization of 13.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 0.36 Cr, while the sum of Net Profit for the same period is 0.43 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds stand at 7.71 Cr, and Total Assets are valued at 9.22 Cr.

Who are in the management team of Emmessar Biotech?

The management team of Emmessar Biotech includes MSR Ayyangar (Chairman & Managing Director), Anuradha Raghavan, Sarada Raghavan, Rajalakshmi Srinivasa Raghavan (all Non Executive Directors), Anantharama Sethmani Subramanian and Milind S Desai (Independent Directors), Jayavel Balaiah Nadar (Executive Director & CFO), and Priyanka Omprakash Sharma (Company Secretary & Compliance Officer).

The management team of Emmessar Biotech includes the following individuals:<BR><BR>1. **MSR Ayyangar** - Chairman & Managing Director<BR>2. **Anuradha Raghavan** - Non Executive Director<BR>3. **Sarada Raghavan** - Non Executive Director<BR>4. **Anantharama Sethmani Subramanian** - Independent Director<BR>5. **Jayavel Balaiah Nadar** - Executive Director & CFO<BR>6. **Rajalakshmi Srinivasa Raghavan** - Non Executive Director<BR>7. **Priyanka Omprakash Sharma** - Company Secretary & Compliance Officer<BR>8. **Milind S Desai** - Independent Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Emmessar Biotech?

Emmessar Biotech's peers include Tulasee Bio-Eth., Square Four Pro., and Jayshree Chem., among others. Emmessar has average management risk, below average growth, and a below average capital structure, with a 1-year return of -24.10%.

Peers: The peers of Emmessar Biotech are Tulasee Bio-Eth., Square Four Pro., Jayshree Chem., Vivid Global, Sreechem Resins, Kobo Biotech, Kuwer Industries, Link Pharma Chem, and Lime Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Emmessar Biotech, and Below Average management risk is noted at Jayshree Chem., Vivid Global, Kuwer Industries, Link Pharma Chem, and Lime Chemicals, and the rest. For Growth, Average growth is seen at Jayshree Chem., while Below Average growth is noted at Emmessar Biotech, Vivid Global, Sreechem Resins, Kuwer Industries, Link Pharma Chem, and Lime Chemicals, and the rest. In terms of Capital Structure, Good capital structure is present at Vivid Global, while Below Average capital structure is observed at Emmessar Biotech, Sreechem Resins, Kuwer Industries, Link Pharma Chem, and Lime Chemicals, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Tulasee Bio-Eth. at 127.58%, while the peer with the lowest is Bhagawati Oxygen at -37.07%, and Emmessar Biotech's 1-year return of -24.10% is better than Bhagawati Oxygen's but worse than Tulasee Bio-Eth. Additionally, Sreechem Resins, Emmessar Biotech, Link Pharma Chem, Lime Chemicals, and Bhagawati Oxygen all have negative six-month returns.

When is the next results date for Emmessar Biotech & Nutrition Ltd?

The next results date for Emmessar Biotech & Nutrition Ltd is 12 May 2026.

The next results date for Emmessar Biotech & Nutrition Ltd is scheduled for 12 May 2026.

How has been the historical performance of Emmessar Biotech?

Emmessar Biotech has experienced significant fluctuations in financial performance, with net sales and operating income peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25, while operating profit turned negative and total assets and liabilities increased. The company has shown a consistent zero balance in cash and cash equivalents, indicating poor cash flow.

Answer:<BR>The historical performance of Emmessar Biotech shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Emmessar Biotech's net sales have varied considerably, peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25. The total operating income followed a similar trend, with a high of 6.99 Cr in Mar'21 and a drop to 0.61 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 6.14 Cr in Mar'21 and decreasing to 1.56 Cr in Mar'25. Operating profit (PBDIT) has been negative in recent years, with a loss of 0.95 Cr in Mar'25, contrasting with a profit of 0.85 Cr in Mar'21. Profit after tax has decreased from 1.45 Cr in Mar'21 to 0.32 Cr in Mar'25. The company's total assets have increased from 5.19 Cr in Mar'20 to 9.22 Cr in Mar'25, while total liabilities have also risen from 5.19 Cr to 9.22 Cr in the same period. Cash and cash equivalents have shown a consistent zero balance from Mar'20 to Mar'25, indicating a lack of cash flow from operations. Overall, Emmessar Biotech has experienced a decline in sales and profitability, alongside an increase in total assets and liabilities.

Who are the top shareholders of the Emmessar Biotech?

The top shareholders of Emmessar Biotech include Emmessar Technologies Limited with 21.79%, individual investors with 37.15%, and Sandeep Rao as the highest public shareholder at 2.04%. There are no foreign institutional investors, and no promoter holdings are pledged.

The top shareholders of Emmessar Biotech include the promoters, with Emmessar Technologies Limited holding the largest stake at 21.79%. Additionally, individual investors collectively own 37.15% of the company. The highest public shareholder is Sandeep Rao, who holds 2.04%. There are also two mutual fund schemes that hold a very small percentage of shares (0.05%), and currently, there are no foreign institutional investors (FIIs) involved. Notably, there are no pledged promoter holdings.

Is Emmessar Biotech overvalued or undervalued?

As of April 25, 2023, Emmessar Biotech is rated as risky and overvalued, with a PE ratio of 16.32, a Price to Book Value of 2.12, a troubling ROCE of -104%, and has underperformed the Sensex by declining 26.44% year-to-date.

As of 25 April 2023, the valuation grade for Emmessar Biotech has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial stability. The company is currently assessed as overvalued. Key ratios include a PE ratio of 16.32, a Price to Book Value of 2.12, and a troubling ROCE of -104.00%. <BR><BR>In comparison to its peers, Emmessar Biotech's PE ratio is significantly lower than that of Solar Industries, which stands at 123.77, and Godrej Industries at 46.63, both of which are considered very expensive. The negative EV to EBIT and EV to EBITDA ratios of -9.07 and -9.44, respectively, further highlight the company's financial challenges. Notably, Emmessar's stock has underperformed relative to the Sensex, particularly year-to-date, where it has declined by 26.44% compared to the Sensex's gain of 5.61%.

What is the technical trend for Emmessar Biotech?

As of May 30, 2025, Emmessar Biotech's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.

As of 30 May 2025, the technical trend for Emmessar Biotech has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish. The Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but mildly bearish monthly. Dow Theory reflects a mildly bearish trend weekly, contrasting with a mildly bullish stance monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish indicators on the weekly MACD and KST.

Has Emmessar Biotech declared dividend?

No Dividend History Available